Trial Profile
A Phase I, Open-Label, Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD0530 in Combination With Carboplatin and Paclitaxel Chemotherapy in Japanese Patients With Advanced Solid Malignancies.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 16 Feb 2010
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Saracatinib (Primary)
- Indications Non-small cell lung cancer; Ovarian cancer
- Focus Adverse reactions
- Sponsors AstraZeneca
- 05 Feb 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 03 Nov 2009 New trial record